Civil Society Letter to Cepheid Requesting Lower Prices for Xpert SARS-CoV-2 Tests and Increased Volumes Distributed to LMICs
Letters • 2021February 25, 2021 — TAG signed onto this letter requesting that diagnostics company Cepheid increase access to Xpert SARS-CoV-2 tests in low- and middle-income countries (LMICs) by committing a greater proportion of its SARS-CoV-2 test manufacturing capacity to LMICs and by lowering cost of its tests for SARS-CoV-2, TB, HIV, HCV, and other diseases to…
Treatment Action Group Statement on the High Price of Cepheid’s Xpert Test for COVID-19
Statement / Press • 2020Cepheid is profiteering during a pandemic, with dangerous consequences for countries with vulnerable populations and health systems. New York, March 27, 2020 — Treatment Action Group calls for Cepheid to immediately lower to US$ 5 the developing country price of its rapid, cartridge-based test for detecting SARS-CoV-2, the virus that causes COVID-19. The U.S. Food…
Fair Pricing for Cepheid Xpert Tests (COVID-19, HIV, TB, HCV)
Webinars • 2020On Friday, April 3, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF), and the Global Coalition of TB Activists (GCTA) held a webinar on the price of Xpert tests for COVID-19, TB, HIV, HCV and other diseases.
Treatment Action Group and AVAC Statement on Pfizer/BioNTech COVID-19 Vaccine Efficacy Announcement
Statement / Press • 2020Treatment Action Group (TAG) and AVAC welcome today’s announcement that preliminary data from the efficacy trial of Pfizer/BioNTech’s mRNA COVID-19 vaccine indicates a high level of protection against COVID-19. Our organizations urge caution, however, given the very limited information that is available only through a company press release.
Public Investment in Bedaquiline Up to Five-Fold That of Johnson & Johnson
Statement / Press • 2020Treatment Action Group’s independent, peer-reviewed analysis found public investment in the development of bedaquiline was up to five times that of Johnson and Johnson. This finding appears in the new PLOS ONE article, “Public Investments in the Clinical Development of Bedaquiline.”
Global Health and Human Rights Organizations Say U.S. Withdrawal from WHO Is Reckless Act That Could Delay Americans’ Access to COVID-19 Solutions and Prolong Global Pandemic
Statement / Press • 2020AVAC, Health GAP and the Treatment Action Group (TAG) strongly condemn the Trump Administration’s withdrawal from the World Health Organization (WHO).
PrEP Disparities, Access & Cost
Webinars PDF • 2019PrEP Disparities, Access & Cost
The High Cost of PrEP: Updates on Community and Health Department Efforts to Get Affordable TDF/FTC (Truvada) to Those Who Need It Most
Webinars • 2019This webinar took place on June 5 and gave an overview of the recent PrEP pricing advocacy that has taken place, and provided information on how webinar attendees can get more involved in ongoing community efforts to make PrEP affordable. We also looked at how health departments might benefit from a drastic reduction in the…
TAG Welcomes HHS Lawsuit Against Gilead; Urges Dramatic Scale-Up of Low-Cost PrEP
Statement / Press • 2019Treatment Action Group (TAG) welcomes the U.S. Department of Health and Human Services (HHS) pursuit of a lawsuit against Gilead Sciences, Inc., the manufacturer of Truvada and Descovy, the only two FDA-approved pills for pre-exposure prophlyaxis (PrEP) to prevent HIV.
The High Cost of PrEP: Updates from the NYC Health Department
Webinars PDF • 2019The High Cost of PrEP: Updates from the NYC Health Department